Skip to main content

Table 5 Correlations of hTERT rs2736100 polymorphism with baseline characteristics of patients in the recurrence and non-recurrence groups

From: The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC)

Characteristic Non-recurrence group Recurrence group
TT + TG (%) GG (%) P TT + TG (%) GG (%) P
187 50 46 29
Tumor size
 <20 mm 127 (67.9) 30 (60.0) 0.293 31 (67.4) 16 (55.2) 0.287
 ≥20 mm 60 (32.1) 20 (40.0)   15 (32.6) 13 (44.8)
Multicentricity
 Yes 115 (61.5) 28 (56.0) 0.532 27 (58.7) 9 (31.0) 0.02
 No 72 (38.5) 14 (28.0)   19 (41.3) 20 (69.0)
Extrathyroidal invasion
 Yes 66 (35.3) 22 (44.0) 0.258 11 (23.9) 22 (75.9) <0.001
 No 121 (64.7) 28 (56.0)   35 (76.1) 7 (24.1)
Lymph node metastasis
 Yes 33 (17.6) 11 (22.0) 0.482 25 (54.3) 23 (79.3) 0.028
 No 154 (82.4) 39 (78.0)   21 (45.7) 6 (20.7)
Pathological type
 Papillary thyroid carcinoma 173 (92.5) 47 (94.0) 0.907 27 (58.7) 10 (34.5) 0.004
 Follicular thyroid carcinoma 8 (4.3) 2 (4.0)   5 (10.9) 2 (6.9)
 Medullary thyroid carcinoma 4 (2.1) 1 (2.0)   8 (17.4) 2 (6.9)
 Undifferentiated carcinoma 2 (1.1) 0   6 (13.0) 15 (51.7)
Tumor stage
 I + II 156 (83.4) 43 (86.0) 0.659 21 (45.7) 9 (31.0)  
 III + IV 31 (16.6) 7 (14.0)   25 (54.3) 20 (69.0) 0.208
  1. hTERT human telomerase reverse transcriptase